Do certain cannabis strains have more pain-relieving properties than others?

0
102

This story originally appeared on Benzinga

Medical grade cannabis product developer Canonic Ltd., a subsidiary of Evogene Ltd. (TASE: EVGN), announced Tuesday that it has seen positive results in preclinical studies in inflammation and pain model systems. The study was conducted at Israel’s Hadassah Medical Center and Migal – Galilee Research Institute in Kiryat Shmona.

Shutterstock

Results confirmed the identification of specific cannabis strains with enhanced anti-inflammatory and analgesic properties for Canonic’s medical cannabis Precise line and led to a patent application.

RELATED: In Missouri, medical marijuana is all the rage

Combat pain with cannabis

Through its Precise product line, Canonic aims to develop medical-grade cannabis flower and oil products that provide patient relief for specific medical indications with a high degree of consistency and specificity in their clinical effects. Canonic’s first product candidates under the Precise program, targeting pain relief and inflammation reduction, are expected to launch in Israel in 2023, followed by expansion in Europe.

“We are pleased with the progress made in these pre-clinical studies, which will now allow us to advance the development of our first products in the Precise line of medicinal cannabis,” said Dr. Arnon Heyman, CEO of Canonic. “These results provide further validation of the power of our computational biology platform, powered by Evogene’s GeneRator AI technology engine. I would like to thank our partners at Hadassah Medical Center and Migal – Galilee Research Institute and look forward to continuing the development of our novel products.”

RELATED: How Israel became the world leader in cannabis research

Preclinical results “impressive”

Canonic expects to continue development of these top-performing strains throughout 2022, including gathering clinical data, with the expectation of launching its first Precise products in Israel in 2023, followed by planned expansion into Europe .

“We would all like to believe that cannabis represents a potential solution for specific, difficult-to-treat conditions such as pain or inflammatory conditions for which we lack ideal treatments,” said Prof. Yossi (Joseph) Tam, Executive Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University and advisor to Canonic. “After all, it would be poetic if the wisdom of nature provided the medicine we haven’t yet developed ourselves.” The ability of Canonic’s medicinal cannabis strains to reduce pain and inflammation in the pre-clinical setting is impressive.”

In addition, the company recently strengthened its management team with the addition of Tanya Damm Bokobza, EVP Business Development, and Dr. Haleli Sharir, Director of Clinical Research.